# A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

> **NCT00976261** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 72 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GSK1614235
- **DRUG:** Sitagliptin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00976261
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-17
- **Primary completion:** 2010-09-05
- **Final completion:** 2010-09-05
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976261, "A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00976261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*